Ardent Health Partners, Inc. (ARDT) Stock Forecast & Price Target

Compare

100 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARDT Analyst Ratings

Moderate Buy

6 Buy

2 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Ardent

Health Partners, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARDT Stock 12 Month Forecast

Average Price Target

$12.98

▲(40.32% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Ardent Health Partners, Inc. in the last 3 months. The average price target is $12.98 with a high forecast of $15.00 and a low forecast of $8.80. The average price target represents a 40.32% change from the last price of $9.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","16":"$16","9.25":"$9.25","11.5":"$11.5","13.75":"$13.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.98,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,9.25,11.5,13.75,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.48,9.904615384615385,10.329230769230769,10.753846153846155,11.178461538461539,11.603076923076923,12.027692307692307,12.452307692307691,12.876923076923077,13.301538461538462,13.726153846153846,14.150769230769232,14.575384615384614,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.48,9.74923076923077,10.018461538461539,10.287692307692309,10.556923076923077,10.826153846153847,11.095384615384615,11.364615384615385,11.633846153846154,11.903076923076924,12.172307692307692,12.441538461538462,12.71076923076923,{"y":12.98,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.48,9.427692307692308,9.375384615384617,9.323076923076924,9.27076923076923,9.21846153846154,9.166153846153847,9.113846153846154,9.061538461538461,9.00923076923077,8.956923076923077,8.904615384615385,8.852307692307694,{"y":8.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.66,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.97,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.59,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$15.00

Average Price Target$12.98

Lowest Price Target$8.80

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Irene Nattel

RBC Capital

$14→$13

Buy

40.54%

Upside

Reiterated

03/09/26

Ardent Health Partners, Inc. (ARDT) Receives a Buy from RBC Capital

David S Macdonald

Truist Financial

$13

Buy

40.54%

Upside

Reiterated

03/09/26

Truist Financial Keeps Their Buy Rating on Ardent Health Partners, Inc. (ARDT)

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Ardent Health Partners, Inc. (NYSE: ARDT) and Caribou Biosciences (NASDAQ: CRBU)

Jason Cassorla

Guggenheim

$15

Buy

62.16%

Upside

Reiterated

03/09/26

Ardent Health Partners, Inc. (ARDT) Gets a Buy from Guggenheim

Unknown Analyst

Stephens

Not Ranked

Stephens

$14

Buy

51.35%

Upside

Reiterated

03/06/26

Stephens Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)

A.J. Rice

UBS

$14→$13

Buy

40.54%

Upside

Assigned

03/06/26

Analysts Offer Insights on Healthcare Companies: BridgeBio Oncology Therapeutics (NASDAQ: BBOT), Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR) and Ardent Health Partners, Inc. (NYSE: ARDT)

Craig Hettenbach

Morgan Stanley

$12

Hold

29.73%

Upside

Assigned

03/06/26

Ardent Health Partners: Cost Efficiencies Balance Utilization Headwinds, Justifying a Hold Rating

Whit Mayo

Leerink Partners

$16→$15

Buy

62.16%

Upside

Reiterated

03/06/26

Ardent Health price target lowered to $15 from $16 at LeerinkArdent Health price target lowered to $15 from $16 at Leerink

Kevin Fischbeck

Bank of America Securities

$8.8

Sell

-4.86%

Downside

Reiterated

03/05/26

Underperform Reiterated on Ardent: Aggressive EBITDA Targets and Reimbursement Risks Undermine Valuation

Ann Hynes

Mizuho Securities

$20→$12

Buy

29.73%

Upside

Reiterated

12/18/25

Ardent Health price target lowered to $12 from $20 at MizuhoArdent Health price target lowered to $12 from $20 at Mizuho

Benjamin Rossi

J.P. Morgan

$15→$12

Hold

29.73%

Upside

Reiterated

11/24/25

Ardent Health price target lowered to $12 from $15 at JPMorganArdent Health price target lowered to $12 from $15 at JPMorgan

Scott Fidel

Goldman Sachs

$19→$12

Hold

29.73%

Upside

Reiterated

11/14/25

Ardent Health price target lowered to $12 from $19 at Goldman SachsArdent Health price target lowered to $12 from $19 at Goldman Sachs

Timothy Greaves

Loop Capital Markets

$17

Buy

83.78%

Upside

Reiterated

11/14/25

Loop Capital Markets Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Irene Nattel

RBC Capital

$14→$13

Buy

40.54%

Upside

Reiterated

03/09/26

Ardent Health Partners, Inc. (ARDT) Receives a Buy from RBC Capital

David S Macdonald

Truist Financial

$13

Buy

40.54%

Upside

Reiterated

03/09/26

Truist Financial Keeps Their Buy Rating on Ardent Health Partners, Inc. (ARDT)

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Ardent Health Partners, Inc. (NYSE: ARDT) and Caribou Biosciences (NASDAQ: CRBU)

Jason Cassorla

Guggenheim

$15

Buy

62.16%

Upside

Reiterated

03/09/26

Ardent Health Partners, Inc. (ARDT) Gets a Buy from Guggenheim

Unknown Analyst

Stephens

Not Ranked

Stephens

$14

Buy

51.35%

Upside

Reiterated

03/06/26

Stephens Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)

A.J. Rice

UBS

$14→$13

Buy

40.54%

Upside

Assigned

03/06/26

Craig Hettenbach

Morgan Stanley

$12

Hold

29.73%

Upside

Assigned

03/06/26

Ardent Health Partners: Cost Efficiencies Balance Utilization Headwinds, Justifying a Hold Rating

Whit Mayo

Leerink Partners

$16→$15

Buy

62.16%

Upside

Reiterated

03/06/26

Ardent Health price target lowered to $15 from $16 at LeerinkArdent Health price target lowered to $15 from $16 at Leerink

Kevin Fischbeck

Bank of America Securities

$8.8

Sell

-4.86%

Downside

Reiterated

03/05/26

Underperform Reiterated on Ardent: Aggressive EBITDA Targets and Reimbursement Risks Undermine Valuation

Ann Hynes

Mizuho Securities

$20→$12

Buy

29.73%

Upside

Reiterated

12/18/25

Ardent Health price target lowered to $12 from $20 at MizuhoArdent Health price target lowered to $12 from $20 at Mizuho

Benjamin Rossi

J.P. Morgan

$15→$12

Hold

29.73%

Upside

Reiterated

11/24/25

Ardent Health price target lowered to $12 from $15 at JPMorganArdent Health price target lowered to $12 from $15 at JPMorgan

Scott Fidel

Goldman Sachs

$19→$12

Hold

29.73%

Upside

Reiterated

11/14/25

Ardent Health price target lowered to $12 from $19 at Goldman SachsArdent Health price target lowered to $12 from $19 at Goldman Sachs

Timothy Greaves

Loop Capital Markets

$17

Buy

83.78%

Upside

Reiterated

11/14/25

Loop Capital Markets Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ardent Health Partners, Inc.

3 Months

xxx

Success Rate

5/6 ratings generated profit

Average Return

+13.80%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +13.80% per trade.

1 Year

Jason CassorlaGuggenheim

Success Rate

2/6 ratings generated profit

Average Return

-11.93%

Copying Jason Cassorla's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -11.93% per trade.

2 Years

xxx

Success Rate

2/6 ratings generated profit

Average Return

-11.93%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -11.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARDT Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARDT has received 10 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. ARDT average Analyst price target in the past 3 months is 12.98.

Each month's total comprises the sum of three months' worth of ratings.

ARDT Financial Forecast

ARDT Earnings Forecast

Next quarter’s earnings estimate for ARDT is $0.18 with a range of $0.12 to $0.27. The previous quarter’s EPS was $0.32. ARDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.

ARDT Sales Forecast

Next quarter’s sales forecast for ARDT is $1.58B with a range of $1.55B to $1.61B. The previous quarter’s sales results were $1.61B. ARDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.

ARDT Stock Forecast FAQ

What is ARDT’s average 12-month price target, according to analysts?

Based on analyst ratings, Ardent Health Partners, Inc.’s 12-month average price target is 12.98.

What is ARDT’s upside potential, based on the analysts’ average price target?

Ardent Health Partners, Inc. has 40.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARDT a Buy, Sell or Hold?

Ardent Health Partners, Inc. has a consensus rating of Moderate Buy which is based on 6 buy ratings, 2 hold ratings and 1 sell ratings.

What is Ardent Health Partners, Inc.’s price target?

The average price target for Ardent Health Partners, Inc. is 12.98. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $8.80. The average price target represents 40.32% Increase from the current price of $9.25.

What do analysts say about Ardent Health Partners, Inc.?

Ardent Health Partners, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of ARDT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ardent Health Partners, Inc. (ARDT) Stock Forecast & Price Target

ARDT Analyst Ratings

ARDT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ardent Health Partners, Inc.

ARDT Analyst Recommendation Trends

ARDT Financial Forecast

ARDT Earnings Forecast

ARDT Sales Forecast

ARDT Stock Forecast FAQ

Detailed List of Analyst Forecasts